EP1047412A1 - New use of local anaesthetics against vascular headaches - Google Patents

New use of local anaesthetics against vascular headaches

Info

Publication number
EP1047412A1
EP1047412A1 EP98963712A EP98963712A EP1047412A1 EP 1047412 A1 EP1047412 A1 EP 1047412A1 EP 98963712 A EP98963712 A EP 98963712A EP 98963712 A EP98963712 A EP 98963712A EP 1047412 A1 EP1047412 A1 EP 1047412A1
Authority
EP
European Patent Office
Prior art keywords
ethyl
phenoxy
amine
propoxy
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98963712A
Other languages
German (de)
English (en)
French (fr)
Inventor
Carl-Johan Dalsgaard
Arne Eek
Lennart Waldenlind
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1047412A1 publication Critical patent/EP1047412A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Definitions

  • the present invention is directed to a new use of [(3-alkoxy-phenoxy)-ethyl]-dialkylamine derivatives. More particularly the invention is directed to the use of [(3-alkoxy-phenoxy)- ethylj-dialkylamine derivatives as a medicament for use in the treatment of vascular headaches, and in particular as a medicament for the treatment of migraine.
  • Migraine is a disorder that exhibits a spectrum of treatment responses in afflicted individuals. Some sufferers are fortunate and the therapy may be over-the-counter remedies or even non-drug regimens using behavior modification, acupuncture, and hypnosis as instruments of aborting the headache. Bed rest, a darkened room, and the use of cold packs applied to the temporal artery and its branches may modify the attack. Sleep also has a beneficial effect in ending an attack. Most patients, however, will require prescription drugs for relief from the migraine. The symptoms most in need of treatment are the head pain and gastrointestinal symptoms. To a lesser degree, photophobia and the aura warrant treatment; the latter may also be quite disturbing and require treatment although its duration is relatively brief.
  • Migraine is also under-treated. Only about 40 percent of females and 30 percent of males utilize prescription drugs (Celentano et al, 1992). However, many of these patients discontinue prescription medication and rely on the over-the-counter remedies.
  • the most common drugs which at present are used for the treatment of migraine and other forms of vascular headaches are inter alia triptanes,ergotamine, aspirin, and NSAIDS.
  • One major problem with the just mentioned drugs is that they often have an onset time of from 60 minutes and up to 4 hours, which is a disadvantage in therapy of vascular headache conditions such as migraine.
  • these drugs are often in forms suitable for oral administration, which often causes problems for the patient since nausea and vomiting is common among patients suffering from migraine, or other forms of vascular headache conditions.
  • WO 98/38998 discloses the use of levobupivacaine and ropivacaine in the treatment of migraine. These local anaesthetics are however structurally distinct from the local anaesthetics used in accordance with the present invention.
  • the drug used to treat the vascular headache condition should preferably have a fast onset of action, and also as few side effects as possible.
  • the problem underlying the present invention is to find a new way of therapy for vascular headache conditions, and in particular migraine.
  • a further problem underlying the present invention is to find a new way of therapy providing a fast onset of action, i.e. a fast pain relief as well as relief of other symptoms associated a vascular headache condition, to the patient suffering from the vascular headache condition.
  • the present invention is directed to the use of a compound of the formula I
  • R represents C 3 -5 alkyl
  • R 2 and R 3 independently represent C 1 - 3 alkyl; or a pharmaceutically acceptable salt thereof ;
  • a further aspect of the present invention is the use of a compound of the formula I above, for the manufacture of a medicament for use in the treatment of migraine.
  • Still a further aspect of the present invention is a method for the treatment of vascular headache conditions, in particular migraine, comprising administering to a subject suffering from said vascular headache condition, an effective amount of a medicament comprising a compound of the formula I as active agent.
  • vascular headache is intended to include any kind of vascular headaches, in particular migraine, cluster headache, post-traumatic headache, tension headache, muscular headache and headaches due to vascular diseases.
  • migraine should be interpreted according to The International Classsification of Migraine, Headache Classification Committee 1988. However, the specified vascular headache conditions are not to be considered as limiting the invention in any way.
  • Cluster headache is most typically defined as the temporal clustering of attacks during periods usually lasting between 2 weeks and 3 months, separated by remissions of at least 14 days, but usually several months - this type of cluster headache is also called “episodic cluster headache”. "Chronic cluster headache” is characterised by absence of remissions of at least 14 days for more than one year (Textbook of pain, p.504, 3 rd edition, 1994).
  • Post-traumatic headache is headache caused as a result of some head trauma (Textbook of pain, p.504, 3 rd edition, 1994).
  • Treatment headache and “muscular headache” belong to the group of headaches formerly described as “muscle contraction”, “psychogenic”, “stress” or “essential” (Textbook of pain, p. 502, 3rd edition 1994).
  • the compounds according to formula I above may also preferably be used for surgery in the nasal area.
  • a therapeutic or prophylactic effect shall preferably have been achieved within 15 minutes from the time of administration.
  • Patients suffering from vascular headache conditions such as migraine, often get a feeling that an attack of headache is approaching.
  • this patient may administer, preferably intranasally, a dosage of a compound of the formula I . Since the active agent of the formula I has a fast onset of action, the attack of approaching headache will be blocked before it has developed into a painful, vascular headache condition.
  • the use in accordance with the present invention also encompasses the administration of a compound of the formula I as an acute rescue medicine.
  • This means that the use of a compound of the formula I is also effective for therapy of fully developed vascular headache conditions such as migraine.
  • the present invention is intended not only to encompass therapeutic treatment of vascular headache conditions, but also prophylactic treatment of vascular headache conditions.
  • the medicament comprising a compound of the formula I above as the active agent may be administered in form of a pharmaceutical formulation, further comprising pharmaceutically acceptable carriers, diluents or adjuvants.
  • the compound according to formula I above may be administered nasally or intravenously.
  • the medicament is administered nasally in form of a spray.
  • spray will be appreciated by a person skilled in the art, but includes a solution which is distributed such as to increase the contact area with the nasal mucosa.
  • Administration of the medicament in form of drops and powders is a further useful alternative.
  • the dose of the active agent of the formula I above will vary depending on the formulation used, as well as on the severity of the vascular headache condition to be treated. A preferred dose is 0.01-200 mg active agent/kg body weight, more preferably 0.1-2 mg active agent/kg body weight. Similar ranges apply if a compound of the formula I is used for prophylactic treatment.
  • Preferred compounds for use as active agents in accordance with the present invention are compounds of the formula I selected from anyone of
  • pancuronium bromide 0.06 mg/kg pancuronium bromide (Pavulon ).
  • the levels of isoflurane, O2, N2O and the end-tidal CO2 (3.5 - 4.5 %) were monitored during the entire experimental period. Core temperature was maintained at 38 ⁇ 0.5 °C with a homeothermic blanket system.
  • the animals were prepared to enable electrical stimulations (3 mA, 2ms, 2 Hz for 5 min) of the sciatic nerve of both legs.
  • 10 - 20 ⁇ l of isopropyl-methyl-[2-(3-n-propoxy-phenoxy)- ethylj-amine (2 %) in a gel formulation (batch TARO-83-2) or, when needed, the vehicle (batch 106-10-2) were applied on the sciatic nerve distal to the stimulation electrodes 10 min prior to stimulation.
  • the nerves were then sectioned proximal to the electrodes, and Evans blue dye (10 mg/ml, kg) was given intravenously 2 min prior to stimulation.
  • Assessment of neurogenic inflammation 10 - 20 ⁇ l of isopropyl-methyl-[2-(3-n-propoxy-phenoxy)- ethylj-amine (2 %) in a gel formulation (batch TARO-83-2) or, when needed, the vehicle (batch 106-10-2) were applied on the sciatic nerve distal
  • the neurogenic inflammation was assessed 5 min after the end of the stimulation by rating the localized extravasation of Evans Blue in the skin area of the hindpaw innervated by the sciatic nerve, using a 4-point scale as shown in Table 1 below. In a preliminary experiment the inability of the vehicle to block the development of the neurogenic inflammation was checked.
  • the gel was prepared by mixing isopropyl-methyl-[2-(3-n-propoxy-phenoxy)-ethyl]-amine and the hydrochloric acid, whereafter a major part of the water was added. The mixture was stirred until all of the isopropyl-methyl-[2-(3-n-propoxy-phenoxy)-ethyI]-amine had dissolved. pH was adjusted to about 4 and the rest of the water was added. The obtained solution was heated to 70 °C, whereafter the hydroxypropylmethylcellulose was added while vigorous stirring. The jelly was finally cooled while stirring, pH was measured and, if necessary, adjusted to 4.0 - 5.5.
  • a compound of the formula I above is administered to migraine patients having moderate to severe pain according to the 4 point verbal rating scale (VRS): none, mild, moderate and severe respectively.
  • VRS verbal rating scale
  • the route of administration is two different types of nasal administration, one anterior application and one dorsonasal application. Each type of administration is having its own placebo control.
  • the patient's visual analogue scale (VAS) score is recorded at baseline.
  • each patient receives 1 puff in each nostril every 2 minutes for a 10 minute period.
  • each patient receives a total of 10 puffs (5 puffs in each nostril) of a compound of the formula I above
  • Adverse events are monitored throughout the treatment period as well as at a follow-up visit after administration of the study drug.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP98963712A 1997-12-19 1998-12-14 New use of local anaesthetics against vascular headaches Ceased EP1047412A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9704770 1997-12-19
SE9704770A SE9704770D0 (sv) 1997-12-19 1997-12-19 New use
PCT/SE1998/002299 WO1999032103A1 (en) 1997-12-19 1998-12-14 New use of local anaesthetics against vascular headaches

Publications (1)

Publication Number Publication Date
EP1047412A1 true EP1047412A1 (en) 2000-11-02

Family

ID=20409476

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98963712A Ceased EP1047412A1 (en) 1997-12-19 1998-12-14 New use of local anaesthetics against vascular headaches

Country Status (18)

Country Link
EP (1) EP1047412A1 (ko)
JP (1) JP2001526217A (ko)
KR (1) KR20010024768A (ko)
CN (1) CN1282241A (ko)
AU (1) AU1898199A (ko)
BR (1) BR9813775A (ko)
CA (1) CA2314452A1 (ko)
EE (1) EE200000394A (ko)
HU (1) HUP0100599A3 (ko)
ID (1) ID26703A (ko)
IL (1) IL136518A0 (ko)
IS (1) IS5534A (ko)
NO (1) NO20003138L (ko)
PL (1) PL341283A1 (ko)
SE (1) SE9704770D0 (ko)
SK (1) SK7832000A3 (ko)
TR (1) TR200001926T2 (ko)
WO (1) WO1999032103A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
WO2000044432A1 (en) 1999-01-27 2000-08-03 Levin Bruce H Compositions, kits, apparatus, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
AU2100901A (en) * 1999-12-15 2001-06-25 Bruce H. Levin Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
MX2018003713A (es) * 2015-09-24 2018-08-15 Teva Pharmaceuticals Int Gmbh Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
KR20190066607A (ko) 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH380746A (de) * 1958-11-06 1964-08-15 Ciba Geigy Verfahren zur Herstellung neuer sekundärer Amine
US3988475A (en) * 1974-02-05 1976-10-26 Istituto Luso Farmaco D'italia S.R.L. Phenoxyalkylamines
AR004691A1 (es) * 1995-10-27 1999-03-10 Astrazeneca Ab Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9932103A1 *

Also Published As

Publication number Publication date
ID26703A (id) 2001-02-01
CA2314452A1 (en) 1999-07-01
IS5534A (is) 2000-06-15
PL341283A1 (en) 2001-04-09
SE9704770D0 (sv) 1997-12-19
SK7832000A3 (en) 2001-02-12
NO20003138L (no) 2000-08-18
IL136518A0 (en) 2001-06-14
JP2001526217A (ja) 2001-12-18
TR200001926T2 (tr) 2000-11-21
WO1999032103A1 (en) 1999-07-01
KR20010024768A (ko) 2001-03-26
NO20003138D0 (no) 2000-06-16
CN1282241A (zh) 2001-01-31
AU1898199A (en) 1999-07-12
EE200000394A (et) 2001-12-17
HUP0100599A3 (en) 2002-04-29
HUP0100599A2 (hu) 2002-02-28
BR9813775A (pt) 2000-10-10

Similar Documents

Publication Publication Date Title
JP4097285B2 (ja) 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
US6248789B1 (en) Administration of ketamine to manage pain and to reduce drug dependency
Catterall et al. Local anesthetics
JP3310982B2 (ja) 男性の勃起機能不全を改善するための剤形及び方法
ES2395462T3 (es) Inhibidores selectivos de la recaptación de norepinefrina-serotonina para el tratamiento del síndrome de fibromialgia, síndrome de fatiga crónica y dolor
KR100810872B1 (ko) 감기 치료용 조성물
US5030645A (en) Method of treating asthma using (S)-α-fluoromethyl-histidine and esters thereof
MXPA96003633A (en) Use of ketamine and device for the nasal and eye administration of ketamine for the management of pain and for detoxification
EP0506658B1 (en) Compositions and method for treating painful, inflammatory or allergic disorders
EP0454617A1 (en) Treatment of sinus headache
JP2009073842A (ja) 苦痛を管理しおよび薬物依存性を軽減するための、ケタミンの投与
Fischer et al. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat
JP6116246B2 (ja) イオントフォレシスにより悪心および片頭痛を治療するための方法
DE69824730T2 (de) Zusammensetzungen, kits und verfahren zur hemmung von zerebralen neurovasculären störungen und muskulärem kopfschmerzen
JP2003521462A (ja) 男性における器質性勃起機能不全治療のための医薬品製造におけるアポモルヒネの使用
US9592239B2 (en) Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
WO1999032103A1 (en) New use of local anaesthetics against vascular headaches
NO309965B1 (no) Oralt farmasøytisk antihostepreparat
EP1318801B1 (en) Topical analgesic compositions containing aliphatic polyamines and methods of using same
JP2005306882A (ja) 感情的不安定の治療のための医薬の製造に有用な組成物
JP7337081B2 (ja) レストレスレッグズ症候群を治療するための治療薬
MXPA00005861A (en) New use of local anaesthetics against vascular headaches
KR20090103656A (ko) 섬유근육통 치료제
CZ20002254A3 (cs) Nové použití lokálních anestetik proti vaskulárním bolestem hlavy
JP4372723B2 (ja) 慢性疼痛の治療のための医薬の製造に有用な組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20000719;LV PAYMENT 20000719;MK PAYMENT 20000719;RO PAYMENT 20000719;SI PAYMENT 20000719

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/135 A, 7A 61P 25/06 B, 7C 07C 217:20 Z

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 20010914

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020311

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1030751

Country of ref document: HK